ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016
BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Expression of concernOpen access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Dual targeting of interlocked PTK2B and MAPK signaling triggers synergistic ferroptosis via autophagic flux disruption in BRAFCell communication and signaling : CCS · 2026Article
- BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFCell reports. Medicine · 2025Article
- Bridging the gap between tumor and disease: Innovating cancer and glioma models.The Journal of experimental medicine · 2025Review
- Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma.The Journal of clinical investigation · 2024Article
- Successes and challenges in modeling heterogeneous BRAFFrontiers in oncology · 2023Review
- BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.Frontiers in oncology · 2023Review
- Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy.Frontiers in oncology · 2023Review
- Secondary Narcolepsy as Worsening Sign in a Pediatric Case of Optic Pathway Glioma.Children (Basel, Switzerland) · 2022Article
- Environmental and sex-specific molecular signatures of glioma causation.Neuro-oncology · 2022Article
- Targeted therapy for pediatric low-grade glioma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models.Science advances · 2020Article
- Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.Neuro-oncology · 2020Article
- Article
- Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors.Frontiers in cell and developmental biology · 2020Review
- Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.Journal of neuro-oncology · 2019Article
- Article
- The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors.OncoTargets and therapy · 2019Article
- Chromatin remodeling defects in pediatric brain tumors.Annals of translational medicine · 2018Review
- Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.Molecular diagnosis & therapy · 2018Review
Corrections and comments
- Expression of concern
Authors and funding
14 authors at 5 institutions in 2 countries.
Aleksandra OlowDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Sabine MuellerBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California.
Xiaodong YangBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California.
Rintaro HashizumeDepartment of Neurological Surgery, Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Justin MeyerowitzBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California.
William WeissBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California.
Adam C ResnickDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Angela J WaandersDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Lukas J A StalpersDepartment of Radiotherapy, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Mitchel S BergerBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California.
Nalin GuptaBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California.
C David JamesDepartment of Neurological Surgery, Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Claudia K PetritschDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Daphne A Haas-KoganBrain Tumor Research Center, University of California, San Francisco, Helen-Diller Cancer Diller Cancer Research Center, San Francisco, California. dhaas-kogan@lroc.harvard.edu.
University of California, San Francisco · USChildren's Hospital of Philadelphia · USNorthwestern University · USUCSF Helen Diller Family Comprehensive Cancer Center · USAmsterdam UMC Location University of Amsterdam · NL
Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6MClinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9MPrecision Medicine For Pediatric Low-Grade GliomasR01NS091620 · NINDS · DANA-FARBER CANCER INST · PI HAAS-KOGAN, DAPHNE A., RESNICK, ADAM CAIN · 2015 to 2019
$2.6MPediatric low-grade gliomas: biology and molecular targeting.R01NS085336 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI RESNICK, ADAM CAIN · 2014 to 2018
$1.8MBRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to TherapyR01NS080619 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES, CHARLES DAVID, PETRITSCH, CLAUDIA KATHARINA · 2012 to 2016
$1.8MA causal role for asymmetric cell division defects in glioma initiationR01CA164746 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETRITSCH, CLAUDIA KATHARINA · 2012 to 2016
$1.6MTargeting histone demethylase activity for the treatment of pediatric brainstem gliomaR01NS093079 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HASHIZUME, RINTARO · 2015 to 2019
$1.5MInvestigating ASPM regulation of asymmetric division for therapeutic opportunitiesR21NS099836 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETRITSCH, CLAUDIA KATHARINA · 2016 to 2017
$436kNCATS NIH HHS KL2 TR000143NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA164746NIGMS NIH HHS T32 GM007618NINDS NIH HHS R01 NS080619NINDS NIH HHS R01 NS085336NINDS NIH HHS R01 NS091620NINDS NIH HHS R01 NS093079NINDS NIH HHS R21 NS099836
Abstract
purposeAlteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade gliomas (PLGGs), and mTOR activation has been documented in the majority of these tumors. We investigated combinations of MEK1/2, BRAF EXPERIMENTAL
designWe used human glioma lines containing BRAF
resultsIn BRAF
conclusionsIn BRAF
Indexed as
AnimalsAntineoplastic AgentsBenzimidazolesCell LineCell Line, TumorCell SurvivalGliomaHumansIndolesMAP Kinase Kinase 1MAP Kinase Kinase 2MiceNIH 3T3 CellsProto-Oncogene Proteins B-rafS PhaseSulfonamidesAntineoplastic AgentsAZD 6244BenzimidazolesIndolesMAP Kinase Kinase 1MAP Kinase Kinase 2PLX 4720Proto-Oncogene Proteins B-rafSulfonamidesTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.